Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials
CD20-positive Non-Hodgkin Lymphoma
DRUG: Rituximab + MG4101
Overall response rate, Investigator-assessed, confirmed objective response by revised response criteria, Through treatment completion, an average of 25 weeks
Complete remission rate, Confirmed complete remission by revised response criteria, Through treatment completion, an average of 25 weeks|Progression-free survival, PFS as defined by revised response criteria, From date of initiation until the date of first documented progression, whichever came first, assessed up to 2 years|Overall survival, OS as defined by revised response criteria, Through study completion, an average of 2 years
Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy.